However, due to considerable variations in therapeutic strategies adopted by previous research and the scarcity of related investigations, the impact of HER2 expression status on the efficacy and prognostic differences of TCbHP-based dual-target NAT in BC patients remains largely elusive (15–19). Here, BRD2 is linked to breast cancer.